Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback